|
On April 12, 2011 the FDA Oncologic Drugs Advisory Committee (ODAC) will meet to discuss supplemental New Drug Applications for:
- Afinitor or "RAD001" (everolimus) tablets for the treatment of patients with advanced neuroendocrine tumors of gastrointestinal, lung, or pancreatic origin.
- Sutent (sunitinib malate) capsules for the treatment of unresectable pancreatic endocrine tumors.
Click here for more details from the FDA's website.
The FDA is inviting interested individuals to present data, information, and stories.
CFCF would like to address the FDA on behalf of neuroendocrine cancer patients and we need your help. Please help by sharing your experiences - good or bad - with Afinitor or Sutent.
Patients, please either fill out this survey or email Lauren about your experiences with Sutent or Afinitor. The hearing is on April 12, so we need your feedback quickly, by Wednesday, March 23. Please forward this information to anyone you think might be interested in participating.
To take our quick survey, please click here. There are fewer than ten questions; please take the survey today!
Finally, patients are invited to share their stories directly with the FDA. Please call (617.948.2514) or email Lauren by Wednesday, March 23 if you are interested in participating.
| 
